gip/glp-1 receptor agonist GLP-1 Agonists Explained for Pharmacy & Medical Students: Mechanism, Uses, and Side Effects Frontiers | Clinical perspectives on
Description
Gasbjerg LS, Helsted MM, Hartmann B, Jensen MH, Gabe MBN, Sparre-Ulrich AH, et al
In the SURPASS and SURMOUNT trials, Lilly has so far compared tirzepatide to older treatments or placebo (for T2D and obesity)
This includes structured dietary approaches such as portion control, increased protein intake (1.2 to 1.6 grams per kilogram of body weight daily, with caution in chronic kidney disease), and emphasis on whole foods with high satiety value
Mostel Z, Perl A, Marck M, Mehdi SF, Lowell B, Bathija S, et al
S.MassaroJ
Zepbound for chronic weight management in obesity)
